Core Viewpoint - The company expects a significant increase in net profit attributable to equity holders, projecting over 240 million yuan by 2025, which represents a year-on-year growth of approximately 139.4% compared to 100 million yuan for the year ending December 31, 2024 [1] - Revenue is anticipated to exceed 1.05 billion yuan, reflecting a year-on-year increase of about 34.6% from 780 million yuan for the year ending December 31, 2024 [1] Group 1 - The improvement in performance is driven by three main factors: strong domestic sales growth of flagship products, including the Qilin blood flow guiding device, neurovascular guide wires, UltraFree drug-eluting PTA balloon dilatation catheters, and Swan venous intraluminal radiofrequency closure catheters [1] - International sales have more than doubled year-on-year [1] - The company has maintained a relatively stable gross margin while continuously improving operational efficiency [1]

Core Viewpoint - The company expects a significant increase in net profit attributable to equity holders, projecting over RMB 240 million for the year ending December 31, 2025, which represents a year-on-year growth of approximately 139.4% compared to RMB 100.3 million for the year ending December 31, 2024 [1] - The group's revenue is anticipated to exceed RMB 1.05 billion, marking a year-on-year increase of about 34.6% from RMB 780 million for the year ending December 31, 2024 [1] Group Performance Factors - Strong domestic sales growth of several flagship products, including the Qilin blood flow guiding device, neurovascular guide wires, UltraFree drug-eluting PTA balloon dilation catheters, and Swan venous intraluminal radiofrequency closure catheters [1] - Successful market expansion in multiple regions leading to international sales growth of over 100% year-on-year [1] - Relatively stable gross margins combined with ongoing improvements in operational efficiency [1]

Core Viewpoint - The company expects a significant increase in net profit attributable to equity holders, projecting over RMB 240 million for the year ending December 31, 2025, which represents a year-on-year growth of approximately 139.4% compared to RMB 100.3 million for the year ending December 31, 2024 [1] - The group's revenue is anticipated to exceed RMB 1.05 billion, marking a year-on-year increase of about 34.6% from RMB 780 million for the year ending December 31, 2024 [1] Group Performance Drivers - Strong domestic sales growth of several flagship products, including the Qilin blood flow guiding device, neurovascular guidewires, UltraFree drug-eluting PTA balloon dilatation catheters, and Swan venous intraluminal radiofrequency closure catheters [1] - Successful market expansion in multiple regions leading to international sales growth of over 100% year-on-year [1] - Relatively stable gross margins combined with continuously improving operational efficiency [1]

Core Viewpoint - The company, Greechuang Tongqiao (02190.HK), anticipates significant growth in its financial performance for the year ending December 31, 2025, with net profit and revenue projections showing substantial increases compared to the previous year [1] Financial Performance - The expected net profit attributable to equity holders is projected to exceed RMB 240 million, representing a year-on-year increase of approximately 139.4% from RMB 100 million for the year ending December 31, 2024 [1] - The anticipated group revenue is expected to surpass RMB 1.05 billion, reflecting a year-on-year growth of about 34.6% from RMB 780 million for the year ending December 31, 2024 [1] Growth Drivers - The significant improvement in performance is driven by three main factors: 1. Strong domestic sales growth of several flagship products, including the Qilin blood flow guiding device, neurovascular guide wires, UltraFree drug-eluting PTA balloon catheters, and Swan venous endovenous radiofrequency closure catheters [1] 2. Successful market expansion in multiple regions, leading to international sales growth of over 100% year-on-year [1] 3. Relatively stable gross margins combined with continuously improving operational efficiency [1]